1. Chromosomes and Gene Expression
  2. Cancer Biology

Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma

  1. Andrew R Conery
  2. Richard C Centore
  3. Adrianne Neiss
  4. Patricia J Keller
  5. Shivangi Joshi
  6. Kerry L Spillane
  7. Peter Sandy
  8. Charlie Hatton
  9. Eneida Pardo
  10. Laura Zawadzke
  11. Archana Bommi-Reddy
  12. Karen E Gascoigne
  13. Barbara M Bryant
  14. Jennifer A Mertz
  15. Robert J Sims  Is a corresponding author
  1. Constellation Pharmaceuticals, United States
  2. Genentech, United States
https://doi.org/10.7554/eLife.10483
Share this article
Cite this article
  1. Andrew R Conery
  2. Richard C Centore
  3. Adrianne Neiss
  4. Patricia J Keller
  5. Shivangi Joshi
  6. Kerry L Spillane
  7. Peter Sandy
  8. Charlie Hatton
  9. Eneida Pardo
  10. Laura Zawadzke
  11. Archana Bommi-Reddy
  12. Karen E Gascoigne
  13. Barbara M Bryant
  14. Jennifer A Mertz
  15. Robert J Sims
(2016)
Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma
eLife 5:e10483.
https://doi.org/10.7554/eLife.10483
  2. Download BibTeX
  3. Download .RIS

Abstract

Pharmacological inhibition of chromatin co-regulatory factors represents a clinically validated strategy to modulate oncogenic signaling through selective attenuation of gene expression. Here, we demonstrate that CBP/EP300 bromodomain inhibition preferentially abrogates the viability of multiple myeloma cell lines. Selective targeting of multiple myeloma cell lines through CBP/EP300 bromodomain inhibition is the result of direct transcriptional suppression of the lymphocyte-specific transcription factor IRF4, which is essential for the viability of myeloma cells, and the concomitant repression of the IRF4 target gene c-MYC. Ectopic expression of either IRF4 or MYC antagonizes the phenotypic and transcriptional effects of CBP/EP300 bromodomain inhibition, highlighting the IRF4/MYC axis as a key component of its mechanism of action. These findings suggest that CBP/EP300 bromodomain inhibition represents a viable therapeutic strategy for targeting multiple myeloma and other lymphoid malignancies dependent on the IRF4 network.

Article and author information

Author details

  1. Andrew R Conery

    Constellation Pharmaceuticals, Cambridge, United States
    Competing interests
    Andrew R Conery, Employee of Constellation Pharmaceuticals.

  2. Richard C Centore

    Constellation Pharmaceuticals, Cambridge, United States
    Competing interests
    Richard C Centore, Employee of Constellation Pharmaceuticals.

  3. Adrianne Neiss

    Constellation Pharmaceuticals, Cambridge, United States
    Competing interests
    Adrianne Neiss, Employee of Constellation Pharmaceuticals.

  4. Patricia J Keller

    Constellation Pharmaceuticals, Cambridge, United States
    Competing interests
    Patricia J Keller, Employee of Constellation Pharmaceuticals.

  5. Shivangi Joshi

    Constellation Pharmaceuticals, Cambridge, United States
    Competing interests
    Shivangi Joshi, Employee of Constellation Pharmaceuticals.

  6. Kerry L Spillane

    Constellation Pharmaceuticals, Cambridge, United States
    Competing interests
    Kerry L Spillane, Employee of Constellation Pharmaceuticals.

  7. Peter Sandy

    Constellation Pharmaceuticals, Cambridge, United States
    Competing interests
    Peter Sandy, Employee of Constellation Pharmaceuticals.

  8. Charlie Hatton

    Constellation Pharmaceuticals, Cambridge, United States
    Competing interests
    Charlie Hatton, Employee of Constellation Pharmaceuticals.

  9. Eneida Pardo

    Constellation Pharmaceuticals, Cambridge, United States
    Competing interests
    Eneida Pardo, Employee of Constellation Pharmaceuticals.

  10. Laura Zawadzke

    Constellation Pharmaceuticals, Cambridge, United States
    Competing interests
    Laura Zawadzke, Employee of Constellation Pharmaceuticals.

  11. Archana Bommi-Reddy

    Constellation Pharmaceuticals, Cambridge, United States
    Competing interests
    Archana Bommi-Reddy, Employee of Constellation Pharmaceuticals.

  12. Karen E Gascoigne

    Genentech, South San Francisco, United States
    Competing interests
    Karen E Gascoigne, Employee of Genentech.

  13. Barbara M Bryant

    Constellation Pharmaceuticals, Cambridge, United States
    Competing interests
    Barbara M Bryant, Employee of Constellation Pharmaceuticals.

  14. Jennifer A Mertz

    Constellation Pharmaceuticals, Cambridge, United States
    Competing interests
    Jennifer A Mertz, Employee of Constellation Pharmaceuticals.

  15. Robert J Sims

    Constellation Pharmaceuticals, Cambridge, United States
    For correspondence
    robert.sims@constellationpharma.com
    Competing interests
    Robert J Sims, Employee of Constellation Pharmaceuticals.

Reviewing Editor

  1. Scott A Armstrong, Memorial Sloan Kettering Cancer Center, United States

Version history

  1. Received: July 30, 2015
  2. Accepted: January 4, 2016
  3. Accepted Manuscript published: January 5, 2016 (version 1)
  4. Version of Record published: February 23, 2016 (version 2)
  5. Version of Record updated: July 14, 2016 (version 3)

Copyright

© 2016, Conery et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,990
    views
  • 1,277
    downloads
  • 93
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Andrew R Conery
  2. Richard C Centore
  3. Adrianne Neiss
  4. Patricia J Keller
  5. Shivangi Joshi
  6. Kerry L Spillane
  7. Peter Sandy
  8. Charlie Hatton
  9. Eneida Pardo
  10. Laura Zawadzke
  11. Archana Bommi-Reddy
  12. Karen E Gascoigne
  13. Barbara M Bryant
  14. Jennifer A Mertz
  15. Robert J Sims
(2016)
Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma
eLife 5:e10483.
https://doi.org/10.7554/eLife.10483

Share this article

https://doi.org/10.7554/eLife.10483

Categories and tags

Research organism

Further reading

    1. Chromosomes and Gene Expression
    2. Genetics and Genomics

    Evolutionary adaptation of an HP1-protein chromodomain integrates chromatin and DNA sequence signals

    Lisa Baumgartner, Jonathan J Ipsaro ... Julius Brennecke
    Research Advance

    Members of the diverse heterochromatin protein 1 (HP1) family play crucial roles in heterochromatin formation and maintenance. Despite the similar affinities of their chromodomains for di- and tri-methylated histone H3 lysine 9 (H3K9me2/3), different HP1 proteins exhibit distinct chromatin-binding patterns, likely due to interactions with various specificity factors. Previously, we showed that the chromatin-binding pattern of the HP1 protein Rhino, a crucial factor of the Drosophila PIWI-interacting RNA (piRNA) pathway, is largely defined by a DNA sequence-specific C2H2 zinc finger protein named Kipferl (Baumgartner et al., 2022). Here, we elucidate the molecular basis of the interaction between Rhino and its guidance factor Kipferl. Through phylogenetic analyses, structure prediction, and in vivo genetics, we identify a single amino acid change within Rhino’s chromodomain, G31D, that does not affect H3K9me2/3 binding but disrupts the interaction between Rhino and Kipferl. Flies carrying the rhinoG31D mutation phenocopy kipferl mutant flies, with Rhino redistributing from piRNA clusters to satellite repeats, causing pronounced changes in the ovarian piRNA profile of rhinoG31D flies. Thus, Rhino’s chromodomain functions as a dual-specificity module, facilitating interactions with both a histone mark and a DNA-binding protein.

    1. Biochemistry and Chemical Biology
    2. Chromosomes and Gene Expression

    Human DDX6 regulates translation and decay of inefficiently translated mRNAs

    Ramona Weber, Chung-Te Chang
    Research Article

    Recent findings indicate that the translation elongation rate influences mRNA stability. One of the factors that has been implicated in this link between mRNA decay and translation speed is the yeast DEAD-box helicase Dhh1p. Here, we demonstrated that the human ortholog of Dhh1p, DDX6, triggers the deadenylation-dependent decay of inefficiently translated mRNAs in human cells. DDX6 interacts with the ribosome through the Phe-Asp-Phe (FDF) motif in its RecA2 domain. Furthermore, RecA2-mediated interactions and ATPase activity are both required for DDX6 to destabilize inefficiently translated mRNAs. Using ribosome profiling and RNA sequencing, we identified two classes of endogenous mRNAs that are regulated in a DDX6-dependent manner. The identified targets are either translationally regulated or regulated at the steady-state-level and either exhibit signatures of poor overall translation or of locally reduced ribosome translocation rates. Transferring the identified sequence stretches into a reporter mRNA caused translation- and DDX6-dependent degradation of the reporter mRNA. In summary, these results identify DDX6 as a crucial regulator of mRNA translation and decay triggered by slow ribosome movement and provide insights into the mechanism by which DDX6 destabilizes inefficiently translated mRNAs.